Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Why We Need Proper PBPK Models to Examine Intestine and Liver Oral Drug Absorption

Author(s): Edwin C.Y. Chow and K. Sandy Pang

Volume 14, Issue 1, 2013

Page: [57 - 79] Pages: 23

DOI: 10.2174/1389200211309010057

Price: $65

Abstract

Intestinal transporters and enzymes are factors that can influence the absorption of orally administrated drugs. Compartmental models are no longer adequate to describe the sequential handling of drugs and metabolites by the intestine and liver during oral drug absorption, especially when intestinal removal is substantial relative to the liver, and when induction/inhibition elicits different extents of change for identical intestinal and hepatic enzymes or transporters. In this review, we described PBPK models for the intestine (with differential flow patterns: traditional model, TM, and segregated flow model, SFM, and QGut model) as well as semi- or whole bodyphysiological- based pharmacokinetic (PBPK) models to describe the impact of the flow pattern, and the intestinal transporters and enzymes and their attendant heterogeneities on intestinal (FI or FG) and oral (Fsys) bioavailability. The modeling efforts have led to a refinement in providing mechanistic insight on the accurate prediction of drug and metabolite profiles for DDI, pharmacogenomics, age factors and disease conditions.

Keywords: Intestine models; segregated flow model, QGut model, physiological-based pharmacokinetic (PBPK) models, enzymes; transporters; intestinal flow, enterocyte flow


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy